(KVUE) Kenvue - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US49177J1025
Stock: Medicines, Skincare, Baby Care, Oral Care, Vitamins
Total Rating 39
Risk 56
Buy Signal -0.64
| Risk 5d forecast | |
|---|---|
| Volatility | 28.5% |
| Relative Tail Risk | -11.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.67 |
| Alpha | -22.91 |
| Character TTM | |
|---|---|
| Beta | -0.081 |
| Beta Downside | -0.555 |
| Drawdowns 3y | |
|---|---|
| Max DD | 44.08% |
| CAGR/Max DD | -0.22 |
EPS (Earnings per Share)
Revenue
Description: KVUE Kenvue March 05, 2026
Kenvue Inc. is a consumer health company operating globally across North America, Europe, Africa, Asia-Pacific, and Latin America.
The company segments its operations into Self Care, Skin Health and Beauty, and Essential Health. The consumer health sector is characterized by a high volume of repeat purchases and brand loyalty.
Kenvue offers a wide range of products including over-the-counter medicines, skincare, oral care, and baby care. This business model relies on a diverse portfolio of established brands, such as Tylenol, Neutrogena, and Listerine, to capture various consumer needs.
Kenvue Inc. was incorporated in 2022 and is based in Summit, New Jersey. To further analyze Kenvues market position, consider exploring its financial performance data on platforms like ValueRay.
Headlines to watch out for
- Consumer health product demand drives revenue growth
- Raw material costs impact profit margins
- Regulatory changes affect product approvals
- Competition from generics pressures pricing
- Global economic stability influences consumer spending
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 1.47b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.15 > 1.0 |
| NWC/Revenue: -1.64% < 20% (prev -1.38%; Δ -0.26% < -1%) |
| CFO/TA 0.08 > 3% & CFO 2.20b > Net Income 1.47b |
| Net Debt (7.46b) to EBITDA (2.96b): 2.52 < 3 |
| Current Ratio: 0.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.92b) vs 12m ago -0.47% < -2% |
| Gross Margin: 58.13% > 18% (prev 0.58%; Δ 5755 % > 0.5%) |
| Asset Turnover: 57.42% > 50% (prev 60.37%; Δ -2.95% > 0%) |
| Interest Coverage Ratio: 5.94 > 6 (EBITDA TTM 2.96b / Interest Expense TTM 405.0m) |
Altman Z'' 0.20
| A: -0.01 (Total Current Assets 5.70b - Total Current Liabilities 5.95b) / Total Assets 27.08b |
| B: -0.01 (Retained Earnings -204.0m / Total Assets 27.08b) |
| C: 0.09 (EBIT TTM 2.40b / Avg Total Assets 26.34b) |
| D: -0.32 (Book Value of Equity -5.14b / Total Liabilities 16.31b) |
| Altman-Z'' Score: 0.20 = B |
Beneish M -3.14
| DSRI: 0.92 (Receivables 2.38b/2.66b, Revenue 15.12b/15.46b) |
| GMI: 1.00 (GM 58.13% / 57.97%) |
| AQI: 0.99 (AQ_t 0.71 / AQ_t-1 0.71) |
| SGI: 0.98 (Revenue 15.12b / 15.46b) |
| TATA: -0.03 (NI 1.47b - CFO 2.20b) / TA 27.08b) |
| Beneish M-Score: -3.14 (Cap -4..+1) = AA |
What is the price of KVUE shares?
As of March 11, 2026, the stock is trading at USD 17.96 with a total of 30,105,192 shares traded.
Over the past week, the price has changed by -1.05%, over one month by -0.84%, over three months by +4.89% and over the past year by -21.68%.
Over the past week, the price has changed by -1.05%, over one month by -0.84%, over three months by +4.89% and over the past year by -21.68%.
Is KVUE a buy, sell or hold?
Kenvue has received a consensus analysts rating of 3.42.
Therefor, it is recommend to hold KVUE.
- StrongBuy: 3
- Buy: 2
- Hold: 14
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the KVUE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 19.8 | 10.4% |
| Analysts Target Price | 19.8 | 10.4% |
KVUE Fundamental Data Overview March 09, 2026
P/E Trailing = 24.1974
P/E Forward = 16.4474
P/S = 2.3306
P/B = 3.2495
P/EG = 1.5659
Revenue TTM = 15.12b USD
EBIT TTM = 2.40b USD
EBITDA TTM = 2.96b USD
Long Term Debt = 6.94b USD (from longTermDebt, last quarter)
Short Term Debt = 1.45b USD (from shortTermDebt, last quarter)
Debt = 8.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.46b USD (from netDebt column, last quarter)
Enterprise Value = 42.71b USD (35.25b + Debt 8.52b - CCE 1.06b)
Interest Coverage Ratio = 5.94 (Ebit TTM 2.40b / Interest Expense TTM 405.0m)
EV/FCF = 24.80x (Enterprise Value 42.71b / FCF TTM 1.72b)
FCF Yield = 4.03% (FCF TTM 1.72b / Enterprise Value 42.71b)
FCF Margin = 11.39% (FCF TTM 1.72b / Revenue TTM 15.12b)
Net Margin = 9.72% (Net Income TTM 1.47b / Revenue TTM 15.12b)
Gross Margin = 58.13% ((Revenue TTM 15.12b - Cost of Revenue TTM 6.33b) / Revenue TTM)
Gross Margin QoQ = 56.53% (prev 59.14%)
Tobins Q-Ratio = 1.58 (Enterprise Value 42.71b / Total Assets 27.08b)
Interest Expense / Debt = 1.15% (Interest Expense 98.0m / Debt 8.52b)
Taxrate = 22.72% (97.0m / 427.0m)
NOPAT = 1.86b (EBIT 2.40b * (1 - 22.72%))
Current Ratio = 0.96 (Total Current Assets 5.70b / Total Current Liabilities 5.95b)
Debt / Equity = 0.79 (Debt 8.52b / totalStockholderEquity, last quarter 10.77b)
Debt / EBITDA = 2.52 (Net Debt 7.46b / EBITDA 2.96b)
Debt / FCF = 4.33 (Net Debt 7.46b / FCF TTM 1.72b)
Total Stockholder Equity = 10.55b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.58% (Net Income 1.47b / Total Assets 27.08b)
RoE = 13.94% (Net Income TTM 1.47b / Total Stockholder Equity 10.55b)
RoCE = 13.75% (EBIT 2.40b / Capital Employed (Equity 10.55b + L.T.Debt 6.94b))
RoIC = 9.68% (NOPAT 1.86b / Invested Capital 19.20b)
WACC = 4.70% (E(35.25b)/V(43.77b) * Re(5.62%) + D(8.52b)/V(43.77b) * Rd(1.15%) * (1-Tc(0.23)))
Discount Rate = 5.62% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.13%
[DCF] Terminal Value 85.07% ; FCFF base≈1.57b ; Y1≈1.39b ; Y5≈1.16b
[DCF] Fair Price = 14.49 (EV 35.24b - Net Debt 7.46b = Equity 27.78b / Shares 1.92b; r=5.90% [WACC]; 5y FCF grow -13.72% → 2.90% )
EPS Correlation: -30.42 | EPS CAGR: 6.50% | SUE: 2.59 | # QB: 2
Revenue Correlation: 9.18 | Revenue CAGR: 1.38% | SUE: 1.22 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.31 | Chg7d=-0.000 | Chg30d=+0.006 | Revisions Net=+2 | Analysts=8
EPS current Year (2026-12-31): EPS=1.13 | Chg7d=+0.004 | Chg30d=+0.024 | Revisions Net=+7 | Growth EPS=+4.3% | Growth Revenue=+2.8%
EPS next Year (2027-12-31): EPS=1.20 | Chg7d=+0.000 | Chg30d=+0.023 | Revisions Net=+5 | Growth EPS=+6.5% | Growth Revenue=+2.6%
[Analyst] Revisions Ratio: +0.50 (3 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.8% (Discount Rate 7.9% - Earnings Yield 4.1%)
[Growth] Growth Spread = -0.9% (Analyst 3.0% - Implied 3.8%)
P/E Forward = 16.4474
P/S = 2.3306
P/B = 3.2495
P/EG = 1.5659
Revenue TTM = 15.12b USD
EBIT TTM = 2.40b USD
EBITDA TTM = 2.96b USD
Long Term Debt = 6.94b USD (from longTermDebt, last quarter)
Short Term Debt = 1.45b USD (from shortTermDebt, last quarter)
Debt = 8.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.46b USD (from netDebt column, last quarter)
Enterprise Value = 42.71b USD (35.25b + Debt 8.52b - CCE 1.06b)
Interest Coverage Ratio = 5.94 (Ebit TTM 2.40b / Interest Expense TTM 405.0m)
EV/FCF = 24.80x (Enterprise Value 42.71b / FCF TTM 1.72b)
FCF Yield = 4.03% (FCF TTM 1.72b / Enterprise Value 42.71b)
FCF Margin = 11.39% (FCF TTM 1.72b / Revenue TTM 15.12b)
Net Margin = 9.72% (Net Income TTM 1.47b / Revenue TTM 15.12b)
Gross Margin = 58.13% ((Revenue TTM 15.12b - Cost of Revenue TTM 6.33b) / Revenue TTM)
Gross Margin QoQ = 56.53% (prev 59.14%)
Tobins Q-Ratio = 1.58 (Enterprise Value 42.71b / Total Assets 27.08b)
Interest Expense / Debt = 1.15% (Interest Expense 98.0m / Debt 8.52b)
Taxrate = 22.72% (97.0m / 427.0m)
NOPAT = 1.86b (EBIT 2.40b * (1 - 22.72%))
Current Ratio = 0.96 (Total Current Assets 5.70b / Total Current Liabilities 5.95b)
Debt / Equity = 0.79 (Debt 8.52b / totalStockholderEquity, last quarter 10.77b)
Debt / EBITDA = 2.52 (Net Debt 7.46b / EBITDA 2.96b)
Debt / FCF = 4.33 (Net Debt 7.46b / FCF TTM 1.72b)
Total Stockholder Equity = 10.55b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.58% (Net Income 1.47b / Total Assets 27.08b)
RoE = 13.94% (Net Income TTM 1.47b / Total Stockholder Equity 10.55b)
RoCE = 13.75% (EBIT 2.40b / Capital Employed (Equity 10.55b + L.T.Debt 6.94b))
RoIC = 9.68% (NOPAT 1.86b / Invested Capital 19.20b)
WACC = 4.70% (E(35.25b)/V(43.77b) * Re(5.62%) + D(8.52b)/V(43.77b) * Rd(1.15%) * (1-Tc(0.23)))
Discount Rate = 5.62% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.13%
[DCF] Terminal Value 85.07% ; FCFF base≈1.57b ; Y1≈1.39b ; Y5≈1.16b
[DCF] Fair Price = 14.49 (EV 35.24b - Net Debt 7.46b = Equity 27.78b / Shares 1.92b; r=5.90% [WACC]; 5y FCF grow -13.72% → 2.90% )
EPS Correlation: -30.42 | EPS CAGR: 6.50% | SUE: 2.59 | # QB: 2
Revenue Correlation: 9.18 | Revenue CAGR: 1.38% | SUE: 1.22 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.31 | Chg7d=-0.000 | Chg30d=+0.006 | Revisions Net=+2 | Analysts=8
EPS current Year (2026-12-31): EPS=1.13 | Chg7d=+0.004 | Chg30d=+0.024 | Revisions Net=+7 | Growth EPS=+4.3% | Growth Revenue=+2.8%
EPS next Year (2027-12-31): EPS=1.20 | Chg7d=+0.000 | Chg30d=+0.023 | Revisions Net=+5 | Growth EPS=+6.5% | Growth Revenue=+2.6%
[Analyst] Revisions Ratio: +0.50 (3 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.8% (Discount Rate 7.9% - Earnings Yield 4.1%)
[Growth] Growth Spread = -0.9% (Analyst 3.0% - Implied 3.8%)